SINT SINTX TECHNOLOGIES INC.

SINTX TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE MAY 28, 2024

SINTX TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE MAY 28, 2024

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) today announced that its Board of Directors has declared a 1-for-200 reverse stock split of the company’s common stock. The reverse stock split will become effective on May 28, 2024 (the “Effective Date”) at 12:01 AM Eastern Time. The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on May 28, 2024 under the current trading symbol “SINT.”

The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the Company’s shares of common stock following the reverse split will be 829392 703.

As a result of the reverse stock split, every 200 shares of the company’s common stock issued and outstanding will be automatically reclassified into one new share of common stock. Proportionate adjustments will be made to the conversion and exercise prices and the number of shares underlying the Company’s outstanding warrants, preferred stock, equity awards and the number of shares reserved under the Company’s equity incentive plan. The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.

The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the company, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share and no stockholders will receive cash in lieu of fractional shares.

The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 123 million to approximately 0.6 million.

The Company’s transfer agent, Equiniti Trust Company LLC, will send each stockholder a transaction statement indicating the number of shares of common stock the stockholder holds after the reverse stock split. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes. Such stockholders will not be required to take any action in connection with the reverse stock split.

Additional information about the reverse stock split and stockholder approval can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2024, which is available free of charge at the SEC’s website, , and at the company’s website, .

About SINTX Technologies

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing facilities in Utah and Maryland.

For more information on SINTX Technologies or its silicon nitride material platform, please visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that implementing a reverse stock split will result in the company regaining compliance with Nasdaq listing requirements or that if compliance is regained that the company will be able to maintain such compliance. A discussion of additional risks and uncertainties can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Contact:

SINTX Technologies 

801.839.3502



EN
23/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies to Participate in Noble Capital Markets’ Emerging G...

SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company’s participation comes at an important stage in its evolution, following a period o...

 PRESS RELEASE

SINTX Technologies to Participate in Sidoti & Company Investor Confere...

SINTX Technologies to Participate in Sidoti & Company Investor Conference SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: To schedule a one-on-one meeting with SINTX Technologies’ management team, please email KCSA Strategic ...

 PRESS RELEASE

SINTX Technologies ลงนามในข้อตกลงจัดหาวัสดุกับ EVONIK เพื่อผลิตสารประก...

SINTX Technologies ลงนามในข้อตกลงจัดหาวัสดุกับ EVONIK เพื่อผลิตสารประกอบซิลิคอนไนไตรด์–PEEK สำหรับรากฟันเทียมเฉพาะบุคคลที่พิมพ์ 3 มิติ โดยใช้เทคโนโลยี AI เข้าช่วย ความสำเร็จครั้งสำคัญช่วยให้สามารถผลิตอุปกรณ์ SiN/PEEK แบบกำหนดเองได้ทันที เมืองซอลต์เลกซิตี รัฐยูทาห์ วันที่ , Dec. 02, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc.  (NASDAQ: SINT) (“SINTX” หรือ “บริษัท”) ซึ่งเป็นบริษัทด้านเซรามิกส์และวัสดุชีวภาพขั้นสูง ได้ประกาศในวันนี้ว่า บริษัทได้ลงนามในข้อตกลงจัดหาวัสดุกับ Evonik Corporation (“EVONIK”) ซึ่งเป็นผู้นำระดับโลกด้านโพลิเมอร์ประสิทธิภาพสูง เพื่อผลิตสารประกอบซิลิคอนไนไตรด์–P...

 PRESS RELEASE

SINTX Technologies 与 EVONIK 签署供应协议,将生产用于人工智能辅助 3D 打印患者定制植入物的氮化硅-PEEK 复...

SINTX Technologies 与 EVONIK 签署供应协议,将生产用于人工智能辅助 3D 打印患者定制植入物的氮化硅-PEEK 复合材料 该里程碑使 SiN/PEEK 定制器械能够立即投产 犹他州盐湖城, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先进陶瓷和生物材料公司 SINTX Technologies, Inc. (NASDAQ: SINT) (简称“SINTX”或“公司”)今天宣布,已与高性能聚合物领域的全球领导企业 Evonik Corporation(简称“EVONIK”)签署供应协议,由 EVONIK 生产 SINTX 的专有氮化硅-PEEK 复合材料(SiN/PEEK,美国专利号 10806831)。该材料专为人工智能辅助的患者定制植入物增材制造而设计,并将使用 SINTX 位于美国的现有生产设施完成制造。 根据协议,EVONIK 将利用其商业规模生产能力,按照 SINTX 的规格生产 SiN/PEEK 复合材料,使 SINTX 能够立即开始制造人工智能设计 3D 打印患者定制植入物。 SINTX 公司已经收到医生提出的请求,希望该公司能为脊柱肿瘤切除术后的骨科和神经外科肿瘤患者提供用于人道主义用途的椎体置换 (VBR) 植入物。 此外,该公司计划使用 SiN/PEEK 复合材料支持患者匹配型植入物及采用传统减材制...

 PRESS RELEASE

SINTX Technologies 與 EVONIK 簽署供應協議,生產用於人工智能輔助 3D 打印患者專屬植入物的氮化矽–PEEK 複合...

SINTX Technologies 與 EVONIK 簽署供應協議,生產用於人工智能輔助 3D 打印患者專屬植入物的氮化矽–PEEK 複合材料 此里程碑讓 SiN/PEEK 定制儀器得以即時投產 猶他州鹽湖城, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先進陶瓷與生物材料公司 SINTX Technologies, Inc. (NASDAQ: SINT) (「SINTX」或「該公司」) 今日宣佈,已與高性能聚合物全球領導者 Evonik Corporation (「EVONIK」) 簽署供應協議,生產該公司專利的氮化矽–PEEK(即聚醚醚酮)複合材料 (SiN/PEEK) (美國專利編號:10,806,831),此材料專為人工智能 (AI) 輔助增材製造患者專屬植入物而設計,將運用 SINTX 美國生產基地現有設備來生產。 根據協議,EVONIK 將發揮達到商業規模的生產能力,按照 SINTX 規格生產 SiN/PEEK 複合材料,使該公司能夠立即開始製造由 AI 設計、3D 打印的患者專屬植入物。SINTX 已收到醫生請求,為脊椎腫瘤切除後的骨科及神經外科腫瘤患者,提供人道使用的椎體替換(VBR)植入式儀器。此外,該公司打算運用 SiN/PEEK 複合材料,支援患者匹配及傳統減材製造植入式儀器的監管批准。 SINTX 主席、董事長暨行...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch